```html

Fusarium Infection – Comprehensive Medical Guide

Overview

Fusarium infection (also called fusariosis) is a fungal disease caused by species of the genus Fusarium. These mold‑like fungi are commonly found in soil, plants, and water worldwide. While many people encounter Fusarium spores without becoming ill, the organisms can cause a range of infections—from superficial skin lesions to life‑threatening bloodstream disease—particularly in individuals with weakened immune systems.

Who it affects

• Immunocompromised patients (e.g., chemotherapy, organ‑transplant, hematologic malignancies, HIV/AIDS)
• People with prolonged neutropenia (low neutrophil count)
• Patients receiving long‑term central venous catheters
• Individuals with extensive burns, traumatic skin injuries, or chronic wounds
• Healthy individuals can develop localized skin or nail infections after contact with contaminated soil or plant material.

Prevalence

• Fusarium is the second most common mold causing invasive disease in hematologic malignancy patients, after Aspergillus (CDC).
• In the United States, invasive fusariosis accounts for roughly 1–2 % of all invasive mold infections, but the rate rises to 5–10 % in centers that perform large numbers of bone‑marrow transplants (Mayo Clinic Proceedings, 2014).
• Outbreaks of cutaneous fusariosis have been reported after natural disasters (e.g., tornadoes, floods) where contaminated debris contacts skin.

Symptoms

General / Systemic Symptoms

• Fever – persistent or recurrent, often unresponsive to antibacterial therapy.
• Chills, sweats, and malaise – common in invasive disease.
• Weight loss, fatigue – may develop over weeks.

Cutaneous (Skin) Manifestations

• Red or pink macules that evolve into painful nodules or ulcers.
• Necrotic centers with black eschar, especially on extremities.
• Vascular lesions that may appear as livedo‑reticularis‑like patterns.
• Subcutaneous nodules that can spread along lymphatic channels (“sporotrichoid” spread).
• Onychomycosis – thickened, discolored nail plates, usually toenails.

Ocular Involvement

• Redness, pain, blurred vision, and photophobia.
• Corneal ulcer or keratitis after trauma with plant material.

Respiratory Tract

• Persistent cough, shortness of breath, chest pain.
• Diffuse infiltrates on chest imaging, sometimes with cavitation.

Sinus and ENT

• Nasal congestion, facial pain, sinusitis that does not improve with antibiotics.

Disseminated (Bloodstream) Infection

• Fever and chills despite broad‑spectrum antibiotics.
• Multiple organ involvement – skin lesions, pneumonia, liver/spleen lesions, CNS symptoms (headache, altered mental status).
• Positive blood cultures for Fusarium (unusual for molds, but occurs in up to 30 % of invasive cases).

Causes and Risk Factors

What causes Fusarium infection?

Fusarium species are ubiquitous environmental molds. Infection occurs when spores (conidia) enter the body through broken skin, the respiratory tract, or (rarely) the gastrointestinal tract. The organism can produce mycotoxins that damage tissue and evade the immune response.

Key risk factors

• Neutropenia – absolute neutrophil count < 500 cells/µL for >10 days dramatically raises risk.
• Prolonged corticosteroid use or other immunosuppressive drugs (e.g., cyclosporine, tacrolimus).
• Hematologic malignancies (acute leukemia, lymphoma) and bone‑marrow transplantation.
• Diabetes mellitus with poor glycemic control, especially with foot ulcers.
• Severe burns or traumatic wounds contaminated with soil or plant material.
• Indwelling catheters (central lines, peritoneal dialysis catheters) that become colonized.
• Environmental exposure – gardening, agriculture, construction, or living in humid climates.

Diagnosis

Clinical Evaluation

Diagnosis begins with a thorough history (exposures, immune status, recent procedures) and physical examination of skin, eyes, and respiratory findings. Suspicion should be high in neutropenic patients who develop fever unresponsive to antibiotics.

Laboratory and Imaging Tests

• Blood cultures – Fusarium is one of the few molds that grow in routine aerobic blood culture bottles; positive in 30‑50 % of disseminated cases.
• Skin or tissue biopsy – Histopathology demonstrates hyaline, septate hyphae; special stains (Gomori methenamine silver, PAS) aid visualization.
• Culture – Tissue or wound specimens plated on Sabouraud dextrose agar; species identification via morphology or MALDI‑TOF.
• Polymerase chain reaction (PCR) assays – Rapid species‑level detection; increasingly used in reference labs.
• Imaging – Chest CT for pulmonary disease (nodules, halo sign, cavitation); MRI for CNS involvement.
• Ophthalmic examination – Slit‑lamp exam and corneal scraping if keratitis suspected.

Diagnostic Criteria (per EORTC/MSG)

In immunocompromised hosts, invasive fusariosis is defined by either:

1. Positive blood culture or tissue culture from a normally sterile site, plus clinical signs, or
2. Histopathologic evidence of hyaline septate hyphae plus a compatible radiologic lesion, even if cultures are negative.

Treatment Options

Antifungal Medications

Fusarium displays variable susceptibility; treatment often requires combination therapy and therapeutic drug monitoring.

• Voriconazole – First‑line oral or IV agent; MICs tend to be lower than for many other molds. Typical dose: 6 mg/kg IV q12h x2 doses, then 4 mg/kg q12h.
• Liposomal Amphotericin B – Preferred for severe or disseminated disease, especially if voriconazole levels are sub‑therapeutic. Dose: 3–5 mg/kg IV daily.
• Posaconazole (delayed‑release tablets or IV) – Useful as step‑down oral therapy or in patients intolerant to voriconazole.
• Combination therapy – Voriconazole + liposomal amphotericin B is commonly employed for invasive disease; synergistic effects observed in vitro.
• Other agents (e.g., itraconazole, terbinafine) have limited activity and are not recommended as monotherapy.

Adjunctive Measures

• Removal of infected catheters or prosthetic devices – Essential to eradicate biofilm‑associated fungus.
• surgical debridement of necrotic skin, sinus, or orbital tissue when feasible.
• Granulocyte colony‑stimulating factor (G‑CSF) – Accelerates neutrophil recovery in neutropenic patients, improving outcomes.

Duration of Therapy

For invasive disease, treatment continues until:

• Clinical signs resolve,
• Radiologic lesions stabilize or improve, and
• Neutrophil count recovers (≥ 500 cells/µL) for at least 2 weeks.
• In practice, 4–6 weeks of IV therapy followed by oral step‑down is typical, but individualized based on response.

Drug‑Specific Considerations

• Voriconazole can cause visual disturbances and hepatotoxicity; monitor liver enzymes and drug levels (target trough 1–5 µg/mL).
• Amphotericin B is nephrotoxic; monitor serum creatinine and electrolytes.
• Posaconazole absorption improves with high‑fat meals; monitor serum levels (target > 1 µg/mL).

Living with Fusarium Infection

Daily Management Tips

• Adhere to antifungal schedule – Set alarms or use a medication organizer.
• Monitor labs – Keep a log of liver, kidney, and complete blood counts; alert your care team to trends.
• Wound care – Daily cleansing with sterile saline, apply prescribed topical agents, and cover with breathable dressings.
• Skin protection – Wear gloves and long sleeves during gardening or any activity that might expose skin to soil.
• Hydration & nutrition – Adequate protein supports wound healing; discuss supplement needs with a dietitian.
• Avoid hot tubs, pools, or any stagnant water – These can harbor Fusarium spores.
• Regular follow‑up – Keep all appointments with infectious disease, dermatology, and ophthalmology as recommended.

Psychosocial Support

Living with a rare invasive fungal infection can be stressful. Consider:

• Joining support groups (e.g., Fungal Infection Foundation).
• Speaking with a mental‑health professional experienced in chronic illness.
• Utilizing patient assistance programs for costly antifungals.

Prevention

Environmental Measures

• Maintain clean indoor air; use HEPA filters in hospital rooms for high‑risk patients.
• Avoid direct contact with soil, compost, or decaying plant material if you are immunocompromised.
• Disinfect surfaces that may be contaminated with Fusarium (e.g., use bleach‑based solutions).

Medical Strategies

• Prophylactic antifungal therapy (e.g., posaconazole) is recommended for patients with prolonged neutropenia during intensive chemotherapy (CDC).
• Prompt removal or replacement of central lines when infection is suspected.
• Implement strict hand‑hygiene and aseptic techniques during invasive procedures.
• Regular skin inspection for early lesions, especially in transplant or burn patients.

Complications

• Disseminated infection – Spreads to lungs, brain, liver, spleen; mortality can exceed 50 % in neutropenic patients.
• Septic shock – Rapid onset of hypotension and multi‑organ failure.
• Vision loss – Keratitis or endophthalmitis can lead to permanent blindness.
• Permanent skin scarring – Necrotic lesions may require reconstructive surgery.
• Chronic osteomyelitis – Rare but reported when infection involves bone.
• Drug toxicity – Nephrotoxicity from amphotericin B, hepatotoxicity from azoles, leading to treatment interruptions.

When to Seek Emergency Care

Sources: CDC (2023). Fusarium infections. Mayo Clinic Proceedings 2014;89(12):1725‑1733. NIH National Library of Medicine. WHO Fungal Disease Report 2022. Cleveland Clinic. Peer‑reviewed mycology journals.

```